Clinical Trial Update: Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy results for Adalimumab in active psoriatic arthritis have been reported; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED